← Back to Search

Enzyme Inhibitor

Wee1 Inhibitor ZN-c3 for Fallopian Tube Cancer

Phase < 1
Waitlist Available
Led By Evthokia Hobbs, M.D.
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to 30 days after last dose of study intervention
Awards & highlights

Summary

This trial tests ZN-c3, a medicine that blocks enzymes needed for cancer cell growth, in patients with advanced or metastatic triple-negative breast cancer or ovarian cancer. By blocking an important enzyme, ZN-c3 aims to stop cancer cells from growing and spreading.

Eligible Conditions
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Carcinoma
  • Peritoneal Cancer
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to 30 days after last dose of study intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to 30 days after last dose of study intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events
Percent decrease of phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 in tumor cells
Secondary study objectives
CBR for ovarian cancer
Clinical benefit rate (CBR)
Overall survival
+2 more
Other study objectives
Cellular and molecular characteristics
ZN-c3 tumor and plasma concentrations

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (wee1 inhibitor ZN-c3)Experimental Treatment1 Intervention
Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityOTHER
994 Previous Clinical Trials
7,386,948 Total Patients Enrolled
OHSU Knight Cancer InstituteLead Sponsor
234 Previous Clinical Trials
2,088,627 Total Patients Enrolled
Evthokia Hobbs, M.D.Principal InvestigatorOHSU Knight Cancer Institute
~0 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top